Anti-CEA-MFEz

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CEA-MFEz

Drug Alias Nameanti-CEA-MFEz

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsCarcinoembryonic antigen related cell adhesion molecule 5 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 5

Therapy Area/IndicationsLung NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesChristie Hospital Nhs Foundation Trust

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCellular Therapeutics Christie Hospital Nhs Foundation Trust

Active IndicationsN/A

Inactive IndicationsLung NeoplasmsOvarian NeoplasmsPancreatic Neoplasms +[6]

Other Information

ATC CodeN/A